|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 25, 2017 ) Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Fibrosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011060467/sample
Report Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
-The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)
For more information about this report at http://www.reportsweb.com/fibrosis-pipeline-review-h2-2017
Reasons to buy
-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Acceleron Pharma Inc
Aelis Farma SAS
Anima Biotech Ltd
Bristol-Myers Squibb Company
Cellmid Ltd
Clementia Pharmaceuticals Inc
Complexa Inc
Confo Therapeutics
EA Pharma Co Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
iBio Inc
Inception Sciences Inc
Isarna Therapeutics GmbH
Kadmon Corp LLC
Kalyra Pharmaceuticals Inc
Morphic Therapeutic Inc
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Proximagen Ltd
Redx Pharma Plc
Ribomic Inc
Scholar Rock Inc
SciFluor Life Sciences LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011060467/discount
List of Tables
Number of Products under Development for Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Fibrosis-Pipeline by Acceleron Pharma Inc, H2 2017
Fibrosis-Pipeline by Aelis Farma SAS, H2 2017
Fibrosis-Pipeline by Anima Biotech Ltd, H2 2017
Fibrosis-Pipeline by Bristol-Myers Squibb Company, H2 2017
Fibrosis-Pipeline by Cellmid Ltd, H2 2017
Fibrosis-Pipeline by Clementia Pharmaceuticals Inc, H2 2017
Fibrosis-Pipeline by Complexa Inc, H2 2017
Fibrosis-Pipeline by Confo Therapeutics, H2 2017
Fibrosis-Pipeline by EA Pharma Co Ltd, H2 2017
Fibrosis-Pipeline by Five Prime Therapeutics Inc, H2 2017
Fibrosis-Pipeline by Genfit SA, H2 2017
Fibrosis-Pipeline by GlycoMimetics Inc, H2 2017
Fibrosis-Pipeline by iBio Inc, H2 2017
Fibrosis-Pipeline by Inception Sciences Inc, H2 2017
Fibrosis-Pipeline by Isarna Therapeutics GmbH, H2 2017
Fibrosis-Pipeline by Kadmon Corp LLC, H2 2017
Fibrosis-Pipeline by Kalyra Pharmaceuticals Inc, H2 2017
Fibrosis-Pipeline by Morphic Therapeutic Inc, H2 2017
Fibrosis-Pipeline by Neumedicines Inc, H2 2017
Fibrosis-Pipeline by Novartis AG, H2 2017
Fibrosis-Pipeline by Palatin Technologies Inc, H2 2017
Fibrosis-Pipeline by Proximagen Ltd, H2 2017
Fibrosis-Pipeline by Redx Pharma Plc, H2 2017
Fibrosis-Pipeline by Ribomic Inc, H2 2017
Fibrosis-Pipeline by Scholar Rock Inc, H2 2017
Fibrosis-Pipeline by SciFluor Life Sciences LLC, H2 2017
Fibrosis-Pipeline by SK Chemicals Co Ltd, H2 2017
Fibrosis-Pipeline by Symic Biomedical Inc, H2 2017
Fibrosis-Dormant Projects, H2 2017
Fibrosis-Dormant Projects, H2 2017 (Contd..1), H2 2017
Fibrosis-Dormant Projects, H2 2017 (Contd..2), H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011060467/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
